SEHK:1801Biotechs
Innovent Biologics (SEHK:1801): Reassessing Valuation After Landmark Nature Phase 3 Mazdutide Publications
Innovent Biologics (SEHK:1801) just hit a scientific milestone, with two Phase 3 trials of its dual GCG/GLP-1 drug mazdutide published back to back in Nature, sharpening the investment case around its diabetes franchise.
See our latest analysis for Innovent Biologics.
The latest Nature publications cap a run of positive catalysts, including NRDL additions and Hang Seng index inclusion. This comes even as the 30 day share price return of minus 7.1% contrasts with a powerful 1 year total...